Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | PLAT | P00750 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228971 | 1.00 | ITGB3 (0.56) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL10724879 | 0.94 | TACR1 (0.61) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL10724885 | 0.94 | TACR1 (0.61) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL10724242 | 0.94 | TACR1 (0.61) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL10724240 | 0.94 | TACR1 (0.61) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL20187267 | 0.92 | KDM1A (0.50) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL20187270 | 0.92 | KDM1A (0.50) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL8258487 | 0.90 | GPR34 (0.63) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL7084689 | 0.90 | ITGB3 (0.66) | ITGB3ITGA2BCTSLTACR1CTSB | |
| SCHEMBL10722503 | 0.90 | GPR34 (0.63) | ITGB3ITGA2BCTSLTACR1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280721-B1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | ONCOPEPTIDES AB (SE) | 2019-05-14 | — | — | US | disclosed |
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | ONCOPEPTIDES AB (SE) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148473-A1 | PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES | CBR3, GRHPR, CTH | ITGB3 4750/4885ITGA2B 4708/4885CTSL 1776/4885 |
| US-10287316-B2 | Process for preparation of nitrogen mustard derivatives | CBR3, GRHPR, CTH | ITGB3 4750/4885ITGA2B 4708/4885CTSL 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.